RecruitingPhase 2NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allogene Therapeutics
- Principal Investigator
- Allogene Study DirectorAllogene Therapeutics, Inc.
- Intervention
- cemacabtagene ansegedleucel(genetic)
- Enrollment
- 250 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (30)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Genesis Cancer and Blood Institute, Hot Springs, Arkansas, United States
- Alta Bates Summit Medical Center, Berkeley, California, United States
- City of Hope, Duarte, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of California, San Diego, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Medical Oncology Hematology Consultants, Newark, Delaware, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
- Advent Health Cancer Institute, Orlando, Florida, United States
- Orlando Health Cancer Institute, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Foresight Diagnostics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06500273 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- ACTIVE NOT RECRUITINGPHASE3NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
- RECRUITINGNANCT04824950Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)Centre Henri Becquerel
See all trials for Primary mediastinal large B-cell lymphoma →